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Glossary of abbreviated terms 
 
AP-ROP, aggressive posterior retinopathy of prematurity  
APLROP, aggressive posteriorly located retinopathy of prematurity 
BEAT-ROP, bevacizumab eliminates the angiogenic threat in ROP 
CGA, corrected gestational age 
CLT, conventional laser treatment 
ET-ROP, early treatment of ROP 
FDA, Food and drug administration 
GA, gestational age 
ICROP, The international classification of retinopathy of prematurity 
ICU, intensive care unit  
IVB, intravitreal bevacizumab 
PPV, pars plana vitrectomy  
RD, retinal detachment 
ROP, retinopathy of prematurity 
SD, standard deviation. 





Overview of the thesis 
 
Retinopathy of prematurity (ROP) is characterised by abnormal retinal angiogenesis 
occurring in premature and low birth weight neonates. In severe cases, it leads to 
proliferative retinopathy, vitreous haemorrhage, retinal detachment and subsequently 
blindness. ROP is one of the most common causes of preventable blindness. According 
to vision 20/20 ROP is the cause of 11% of childhood blindness in South Africa. 
In patients with ROP, blindness or poor vision is most often ascribed to one of the 
following three entities:  
- Threshold disease.  
- Aggressive posterior retinopathy of prematurity (AP-ROP). 
- Stage 3 disease in zone 1 with plus disease. 
In this study, these entities are collectively referred to as “aggressive posteriorly located 
retinopathy of prematurity.” 
Historically patients who were classified with threshold disease were treated with either 
cryotherapy or conventional laser treatment (CLT). Currently the standard of care is to 
treat ROP patients with prethreshold type I disease with CLT. With this approach poor 
outcomes are reduced from 50% to 25%. Though this is an improvement the success rate 
is still poor. 
In search of more effective means to treat ROP, alternatives have been explored. 
Bevacizumab, an anti-vascular endothelial growth factor that is Food and Drug 
Administration (FDA) approved for the treatment of colorectal cancer, has been used off-
label intravitreally in ROP cases. In the Bevacizumab Eliminates the Angiogenic Threat 




zone I with plus, when compared to CLT. A lack of further randomized controlled trials 
on this issue, however, means that we still lack guidelines and treatment protocols to 
direct ROP treatment.  
This study is a retrospective chart review to assess the outcomes of patients with 
aggressive posteriorly located ROP who were injected with intravitreal bevacizumab 
(IVB) at Inkosi Albert Luthuli Central Hospital between 2009 and 2016.  Patient records 
on the hospital data base were analysed. The outcomes were assessed by analysing the 
gestational age, birth weight, corrected gestational age at time of intervention, other 
concurrent or subsequent interventional modalities as well as post intervention 
progression, regression or recurrence of the disease. Findings at discharge, including time 
to complete vascularisation and complications were also assessed. The defaulters were 
assessed separately. 
Of the 33 patients, 64 eyes received IVB for aggressive posteriorly located ROP, of which 
10 patients (20 eyes) defaulted follow up. Therefore 44 eyes of 23 patients were included 
in the main analysis. Of these patients 16 eyes also had CLT and seven eyes had pars 
plana vitrectomies.  Intravitreal bevacizumab was administered at a mean of 35.27 weeks 
postmenstrual age. Regression and full vascularisation was documented in 36 eyes 
(81.8%) while 8 eyes (18.2%) progressed to retinal detachment.  Seven of these eyes had a 
pars plana vitrectomy of which all, but one, had subsequent flat retinae at discharge. 
Thus, only one eye (2.27%) had a permanent inoperable retinal detachment. The eyes that 
progressed to retinal detachment received IVB at a mean of 1.31 weeks later than the eyes 
that regressed and vascularised fully. Of the 20 eyes of the patients who defaulted, five 
eyes (25%) had a permanent or inoperable retinal detachment at late follow up.  
The important findings in our study were firstly that there seems to be a very specific 




towards progression to retinal detachment when this window period was missed. 
Secondly, there was a very high default rate with poorer outcomes seen in patients who 
defaulted treatment or follow-up. Most of the patients who followed up regularly had a 
favourable structural outcome. It is therefore essential to counsel the parents of ROP 
patients and to have measures in place to assure regular follow up.  
In order to manage ROP effectively a multi modal approach is essential. Long term safety 
of IVB still needs to be established by future studies and therefore the potential risks and 
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 Part 1: The Review of Literature 
Introduction 
 
Retinopathy of prematurity (ROP) is one of the most common causes of preventable 
blindness in preterm neonates.(1) South Africa is a middle income country with a 
declining infant mortality rate (32/1000  in 2016).(2) Thus, more infants, and among these 
an increasing number of low birth weight and less mature neonates, survive due to better 
neonatal care. Because these neonates have a higher risk of developing ROP, South Africa 
forms part of the so-called “third epidemic in ROP” (3).  Despite the extent of this 
problem, there are still limited guidelines and protocols to direct the management of 
especially the most severe cases of ROP. With current standard of care treatment 
modalities, such as CLT, outcomes remain poor. Alternative treatment modalities have 
been implemented, however, with limited research regarding their efficacy and safety. 
More studies are needed to evaluate outcomes, guide future management, and safeguard 
medical practitioners against a rising threat of medical malpractice litigation. 
 
Pathogenesis of retinopathy of prematurity 
 
ROP is caused by abnormal retinal angiogenesis in preterm and low birth weight 
neonates. It firstly comprises a delay in retinal vascular development and later also 
vasoproliferation which can lead to retinal detachment.(4) The first phase (22-30 weeks 
postmenstrual age) is characterised by relative hyperoxia and decreased vascular 
endothelial growth factor (VEGF) levels.   The second phase (31-44 weeks postmenstrual 




Retinal angiogenesis starts at 4 months gestation and is only complete at 40 weeks 
gestation.(5)  Exposure of the incompletely vascularised retina to high oxygen 
concentrations during periods of poor oxygen control, leads to down regulation of VEGF 
production and suppression of vessel migration.(6) Subsequently, as the eye grows the 
metabolic demand of the eye increases due to the state of relative hypoxia and thus there 
is an excessive release of VEGF which causes abnormal vasculogenesis. Blindness due to 
ROP is preventable if supplemental oxygen therapy is used appropriately and a screening 
programme is in place.(7) 
 
Screening protocol for retinopathy of prematurity 
 
A proper screening program is essential in order to identify the patients at risk of 
developing ROP, but also to timeously diagnose the patients needing treatment. 
Guidelines developed by the ROP Working Group of South Africa in 2014 suggested the 
following criteria be used for ROP screening:  
• Gestational age (GA) at birth of less than 32 weeks.(7) 
• Birth weight of less than 1500 gram.(7) 
• Preterm neonates weighing 1500-2000 gram, with additional risk factors including 
cardiac arrest, family history of ROP, hypoxic ischaemic encephalopathy, multiple 
blood transfusions, exchange transfusion or suboptimal oxygen monitoring.(7) 
The Working Group also advocated for oxygen saturation levels to be kept between 88 - 
92% in neonates receiving supplemental oxygen as a primary prevention measure.(7) 
Screening can be stopped once the retina is fully vascularised or vascularisation into zone 




worse disease) or if regression of ROP took place (if no abnormal vascular tissue capable 
of activation or progression is present).(7) 
 
Classification of retinopathy of prematurity 
 
The following criteria are the revised criteria according to the International Classification 
of Retinopathy of Prematurity, as formulated by an international consensus group of 
ophthalmologists(8) 
The classification of ROP according to international standards involves types, zones, 
stages and extent of the disease. ROP can be broadly categorized into standard ROP and 
AP-ROP. ROP is additionally sub- classified in terms of the zones in which it occurs.  
Standard retinopathy of prematurity 
The location of disease involvement in zones includes three possible zones 
• Zone I: The innermost circle of which the radius extends from the middle of the 
optic disc to twice the distance between the centre of the disc and the centre of the 
macula. 
• Zone II: An area extending centrifugally from the edge of zone I to the nasal ora 
serrata. 
• Zone III: The residual temporal crescent anterior to zone II. 
Furthermore, the severity of the disease is also classified according to the following 
stages: 





• Stage 2: A ridge of demarcation that rises above the retinal surface. 
• Stage 3: Extra-retinal fibrovascular proliferation or neovascularisation extending 
from the ridge into the vitreous. This stage can be further subdivided into mild, 
moderate and severe. 
• Stage 4A: Partial retinal detachment not involving the fovea.  
• Stage 4B: Partial retinal detachment with the fovea involved. 
• Stage 5: Total retinal detachment 
The extent of disease is described in clock hours or 30-degree sectors. The term “Plus 
disease” indicates a tendency of the disease to progress and is characterised by the 
presence of posterior pole venous dilatation and arterial tortuosity in at least 2 quadrants 
and if it becomes more severe, may include iris new vessels, poor pupillary dilatation and 
vitreous haze. Pre-plus disease is characterised by abnormal dilatation and tortuosity of 
the posterior pole vessels that are insufficient to be diagnosed as plus disease.  
This schema was added based on findings from the ET-ROP study to help to determine 
whether to treat or to observe patients with ROP.(9) 
Type 1: Higher risk patients that need laser photocoagulation within 72 hours 
• Zone I any stage with plus 
• Zone I, stage 3 without plus 
• Zone II, stage 2/3 with plus 
Type 2: Lower risk patients that should be observed twice a week 
• Zone I, Stage 1/2 without plus 




In order to direct appropriate further treatment, and follow up intervals, it is very 
important to classify the patients correctly according to this classification. It is very 
important to be vigilant in diagnosing AP-ROP, which if missed, will have serious 
implications. 
Aggressive posterior retinopathy of prematurity 
Aggressive posterior retinopathy of prematurity (AP-ROP) has also been referred to as 
“Type II ROP” or “Rush disease” and is an uncommon but very severe form of ROP.(8) 
If not treated appropriately and timeously it usually progresses rapidly to stage 5 ROP.(8) 
The characteristics of this type of ROP are the prominence of plus (in all 4 quadrants), 
posterior location (zone I or posterior zone II) and poorly-defined nature.(8) Other 
features include difficulty to distinguish between arterioles and venules due to shunting 
and it usually does not progress through the classical stages.(8) The junction of 
vascularised and avascular retina may appear featureless, with only a flat network of 
neovascularisation and often haemorrhages.(8) Less experienced practitioners can 





Treatment of retinopathy of prematurity 
 
ROP can be treated in various ways, including, but not limited to cryotherapy, 
conventional laser therapy (CLT), vitrectomy, and anti-vascular endothelial growth 
factor. These are briefly reviewed next. 
Cryotherapy 
The multicentre CRYO for ROP (CRYO-ROP) trial showed a decrease in unfavourable 
outcomes and better visual function, when patients with bilateral threshold disease (i.e. 
5 or more clock hours of stage 3 with plus ), were assigned to receive cryotherapy in one 
eye and no therapy for the fellow eye (control).(3) Almost half of the treated eyes had 
visual acuity of worse than 20/200 at 15 years of age.(3) Currently, cryotherapy is in 
general replaced by laser, but it is rarely still used in cases with a poor view of the retina, 
and cases with no equipment or expertise to perform indirect laser.(10) 
Conventional laser therapy 
The Early Treatment of ROP (ET-ROP) trial showed significant improved outcomes with 
early laser treatment of type 1 (High risk), but not with type 2 (Low risk) prethreshold 
patients.(4) Current guidelines therefore recommend laser ablation of the avascular retina 
in type 1 and twice weekly observation of type 2 prethreshold ROP patients.(4) By 
treating the patients earlier, the unfavourable outcomes were decreased by 5% when 
compared to the treatment of threshold disease.(4) 
If type 1 ROP is diagnosed, laser should be initiated within 72 hours.(4) Laser burns 
should be grey to grey-white and spaced one-half burn apart from ora serrata up to the 




aggressive burns.(4) To give laser treatment successfully is a skill that requires training 
and experience.(11) 
CLT has a more predictable outcome and follow up period than IVB, due to many large 
prospective studies that have been published. Follow up time is also relatively shorter 
and there is no unknown potential systemic safety concerns, as there are with anti-
VEGF.(12) 
Disadvantages of CLT include systemic risks due to prolonged anaesthesia and apnoea, 
bradycardia and cardiopulmonary arrest.(13) Ocular complications include misplaced 
laser, vitreous haemorrhage, cataract, glaucoma, cystoid macular oedema, anterior 
segment ischaemia, macular dragging, myopia and phthisis bulbi.(13)  
CLT for standard ROP is usually successful. However progression to retinal detachment 
occurs commonly with AP-ROP.(13) Several authors have reported poor outcomes when 
CLT was administered for AP-ROP, with the prevalence of retinal detachment ranging 
from 13-100%.(13) Other problems with laser for AP-ROP, because of persistent tunica 
vasculosa lentis, is a hazy view and difficulty to identify the border between vascularised 
and non-vascularised retina.(13) Laser therapy can also cause severe restriction in visual 
field due to an extensive area of retina that is ablated when it is required for very posterior 
disease.(13) A study done by Sanghi et al reported several risk factors for progression to 
retinal detachment after CLT including; GA under 29.5 weeks, haemorrhages, a need for 
repeat laser, new onset fibrovascular traction after laser, extensive fibrovascular 
proliferation (more than three clock hours of stage 3) and posterior zone I disease.(14) 
Therefore, although CLT is still the current standard of care modality for most cases of 
ROP, it is still far from the “gold standard”, especially for the more aggressive and 






Lens sparing vitrectomy is indicated when ROP progresses to stage 4A, 4B or stage 5. 
Scleral buckling for Stage 4A is also a treatment option but according to studies, causes 
macular anisometropia and has a much poorer macular reattachment rate (73% after 
vitrectomy compared to 31% after scleral buckling) and therefore should be avoided.(10) 
There are studies that showed good outcomes with early vitrectomy and lensectomy for 
AP-ROP cases that progressed to retinal detachment despite CLT.(15) Vitrectomy is 
therefore a vital “rescue” modality, especially in cases that responded poorly or 
progressed to retinal detachment, despite treatment with other modalities like CLT or 
IVB. 
Anti-vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) plays a very important role in angiogenesis 
in several organs but especially the eyes, lungs and brain.(13) It also plays an important 
role in neuroprotection.(13) Although VEGF is very important for normal development, 
it is also a culprit in the pathogenesis of several diseases. These include diabetic macular 
oedema, neovascular age-related macular degeneration, metastatic tumours and ROP.  
Bevacizumab is one of the anti-VEGF drugs and was approved by the FDA for 
chemotherapy of metastatic colon cancer in 2004.(16) Intravitreal bevacizumab (IVB) is 
however commonly used off-label as treatment for various forms of intraocular 
neovascularization, including use in ROP as monotherapy, but also in combination with 
CLT or vitrectomy.(5) 
Bevacizumab is a 149 KDa, full-length, recombinant humanised monoclonal antibody 
that acts against VEGF-A by binding to its receptors on the surface of endothelial cells.(16) 
Ranibizumab and aflibercept are alternative anti-VEGF drugs that were specifically 




degeneration.(16) The half-life of bevacizumab after intravitreal use in non-vitrectomised 
eyes is 9.82 days, compared to 7.15 days for ranibizumab.(17) Bevacizumab is cheaper 
than the other available anti-VEGF drugs and is therefore more accessible in resource 
limited settings. Bevacizumab was initially thought to be safer than the other available 
anti-VEGF drugs, because it is a larger molecule and considered less likely to cross the 
blood retinal barrier into the systemic circulation. It was, however, found that after IVB 
had been administered, serum levels of VEGF were lowered for a period of at least 7 
weeks.(17)  Ranibizumab on the other hand, lowered VEGF levels in the serum for 2 
weeks, but it returned to normal 4 weeks post injection.(17) This raises the concern that 
ranibizumab may possibly be a safer alternative to bevacizumab.(17) Few small studies 
have shown good outcomes with intravitreal ranibizumab, but in some of the studies the 
recurrence rate was higher when compared to IVB.(18) Particularly in the preterm 
neonate, where vital organs are still developing, it may be a safer option to use 
ranibizumab. Evidence from large prospective studies is however still lacking.(17) 
Before administering IVB it is very important to counsel the parents properly and to 
obtain informed consent.(11) IVB can be administered at the bedside or in theatre. It is 
very important to use a sterile technique to prevent endophthalmitis.(13) Bevacizumab 
0.025ml (0.625mg) is administered at 1.5mm posterior to the limbus via a 32-gauge 
needle.(19)  
Though certain disadvantages and risks are applicable with IVB treatment of ROP, 
certain positive outcomes and advantages are also evident. IVB can cause contraction of 
fibrovascular membranes when used in stage 4/5 ROP with resultant worsening of 
outcome.(20) Due to safety considerations IVB should not be used in ROP anterior to 
posterior zone II.(21) Another disadvantage of bevacizumab, is that it is effective only 
when administered in a certain window period. If administered before this time, there 




is higher.(11) After IVB, vascularization is significantly delayed and therefore long-term 
follow-up is required, which can be burdensome, especially in resource limited 
settings.(12)  Recurrences and progression of ROP do occur in a small but significant 
number of patients. There is also a risk of endophthalmitis or lens damage with IVB.(12) 
There are no long-term studies to prove adverse systemic effects, but some studies did 
show decreased levels of serum VEGF for up to 7 weeks after IVB.(17) This raises 
questions regarding safety, especially concerning neurologic and respiratory 
development.(21)  
IVB has been shown to have a good outcome in cases with stage 3 ROP with plus in zone 
I.(5) The Bevacizumab Eliminates the Angiogenic Threat in ROP (BEAT-ROP) trial, 
showed significantly improved outcomes after first-line IVB (6% of patients had 
recurrences), when compared with laser (42% of patients had recurrences) for these 
patients.(5) AP-ROP in zone I, which usually has a very poor outcome with CLT, also 
showed good outcomes after first-line IVB.(13) IVB has also been used successfully as 
salvage therapy for threshold disease and progressing ROP after laser(19), and in cases 
where a vitreous haemorrhage or poor pupillary dilatation obscures the view to perform 
other interventions.(20) Cases have been described where IVB has been used as 
monotherapy or in combination with vitrectomy or laser, for severe ROP.(5) IVB acts 
more quickly than  CLT. Advantages of IVB are also that it is a relatively cheaper option 
when compared to laser and is quick and easy to administer in either theatre or ICU.(5) 
In a condition where the time window to stop the neovascular drive is often very small, 
quick administration can make the difference between a good and a poor outcome.(7) In 
contrast to CLT the retina still continues to vascularise after IVB.(5) 
It is advisable to refrain from administering IVB prophylactically for ROP, because of 
safety concerns. There are still many unanswered questions such as what is the ideal 




treatment for ROP are not well studied, though the BEAT-ROP study provides a good 
benchmark for further studies. The outcomes are briefly summarised below. 
In the BEAT-ROP study the recurrence rate after IVB for zone I and posterior zone II 
disease combined was 6%, compared to 26% in the laser group. The difference in rate of 
recurrence between the two modalities was much bigger (42% for CLT and 6% for IVB) 
when zone I was assessed alone. Thus the difference in the recurrence rate between IVB 
and CLT for zone I was statistically significant, but not for zone II.(5) The mean period 
for recurrence was 16±4.6 weeks in the IVB group, compared to 6.2±5.7 weeks in the CLT 
group. (5)  
Macular dragging was documented in 1.4% of eyes in the IVB group compared to 30.1% 
in the CLT group.(5)  Vascularisation continued in the IVB group whereas it halted in the 
CLT group.(5)  The rate of progression of ROP and defaulting was not indicated. Seven 
deaths occurred of which five were in the IVB group.(5) This difference is important, even 
though it is not a statistically significant difference, especially since 4 of the 5 cases were 








High default rates occur in several ROP studies. In a large prospective study performed 
at a tertiary hospital (Chris Hani Baragwanath Hospital, Soweto), 48.8% of the 84 patients 
diagnosed with ROP defaulted follow up.(1) Possible reasons for this poor follow up rate 
could be linked to poverty, poor social support structures, transport, and the physical 





There is a big shift in focus from the road accident fund towards medical malpractice 
claims among lawyers, since recent changes to the road accident fund made it more 
difficult for lawyers to succeed in claims.(23) The number of medical malpractice claims 
in excess of 5 million rand increased by 900% over the past decade. ROP cases, specifically 
in the public sector, have become sought-after among some lawyers because they know 
how difficult these cases are to defend and how easy it is to prove that at some point in 
time, medical mismanagement occurred.(23) Resource limitations in the public sector 
leave a lot of room for mismanagement to occur somewhere in the multi-disciplinary 
chain. It is therefore of cardinal importance to conduct further research in this field to 
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OUTCOMES FOLLOWING INTRAVITREAL BEVACIZUMAB FOR 
AGGRESSIVE POSTERIORLY LOCATED RETINOPATHY OF 
PREMATURITY AT A TERTIARY INSTITUTION 
Background Retinopathy of prematurity is an important cause of childhood blindness 
and conventional treatment modalities lead to significant visual morbidity. Alternative 
treatment modalities need to be explored. 
Aim To analyse outcomes following intravitreal bevacizumab (IVB) for the treatment of 
aggressive posteriorly located retinopathy of prematurity (ROP) at a tertiary institution. 
Setting Inkosi Albert Luthuli Central Hospital, a tertiary hospital in Durban, draining 
patients across KwaZulu-Natal. 
Methods A retrospective chart review of patients treated between January 2009 and 
December 2016. Outcomes were assessed by analysing the gestational age, birth weight, 
gestational age at time of intervention, stage and zone of ROP, other concurrent or 
subsequent interventional modalities, as well as progression, regression or recurrence of 
the disease post intervention and complications. Thirty-three patients (64 eyes) received 
IVB, of whom ten patients (20 eyes) defaulted follow up, leaving 23 patients (44 eyes) to 
qualify for the study.  
Results Of the 44 eyes, 36 (81.8%) regressed and vascularised fully or up to the lasered 
retina, 8 (18.2%) progressed to retinal detachment, of which 7 were surgically reattached 
and one (2.3%) remained permanently detached. Of the 20 eyes from the 10 defaulters, 5 
(25%) had inoperable retinal detachments. 
Conclusion The majority of patients, who complied with ROP treatment and were 
followed up regularly, had a favourable structural outcome when IVB was used 




retinal detachment in eyes where IVB was administered relatively later during the course 







Retinopathy of prematurity (ROP) is one of the most common causes of visual morbidity 
and preventable childhood blindness in the world.(1) South Africa is a middle income 
country with a declining infant mortality rate of 32/1000 in 2016.(2) Thus, more infants, 
and among these an increasing number of low birth weight and less mature neonates, 
survive due to better neonatal care. Due to these neonates having a higher risk of 
developing ROP, South Africa forms part of the so-called “third epidemic in ROP”.(3) 
ROP also results in a large number of large medico-legal cases against medical 
professionals. Despite the serious nature and implications of this disease, there is a lack 
of evidence-based guidelines regarding intravitreal bevacizumab (IVB) treatment for 
ROP. A review of outcomes following IVB and subsequent update of the guidelines may 
promote a better outcome for these patients. 
The current standard treatment of ROP, according to the Early Treatment of Retinopathy 
of Prematurity (ET-ROP) study, is conventional laser therapy (CLT) to the peripheral 
avascular retina for prethreshold type I disease, and twice weekly observation of type II 
prethreshold ROP.(4)(5) By treating the patients earlier, the unfavourable outcomes were 
decreased by 5% when compared to the treatment of threshold disease.(4) CLT has a 
predictable outcome, requires a short follow up period and there are no unknown 
potential systemic safety concerns, but  there are also major disadvantages.(5)  
Disadvantages of CLT include systemic risks due to prolonged anaesthesia, apnoea, 
bradycardia and cardiopulmonary arrest.(6) Ocular complications include misplaced 
laser, vitreous haemorrhage, cataract, anterior segment ischaemia, glaucoma, cystoid 




CLT for standard ROP is usually successful, however progression to retinal detachment 
occurs commonly with Aggressive Posterior ROP (AP-ROP), with the prevalence of 
retinal detachment ranging from 13-100%.(6) Thus the problem with laser treatment is 
that it requires a high level of experience and expensive equipment to perform effectively 
and often leads to significant visual morbidity.(6) Therefore, although CLT is still 
regarded as the standard of care for most cases of ROP, it is far from the “gold standard”, 
especially for the more  posteriorly located cases of ROP. 
In a search for alternative treatment modalities, the Bevacizumab Eliminates the 
Angiogenic Threat in Retinopathy of Prematurity (BEAT-ROP) trial, showed that patients 
with stage 3 disease in zone I with plus, had better outcomes when treated with 
intravitreal bevacizumab compared to treatment with CLT.(7)  
Spandau et al reported good outcomes after first-line IVB for AP-ROP in zone I.(6) IVB 
has also been used successfully as monotherapy or in combination with other modalities 
for salvage therapy for threshold disease, progressing ROP after laser and in cases where 
a vitreous haemorrhage or poor pupillary dilatation obscures the view to perform 
CLT.(8,9) Although some clinicians report improved outcomes with IVB treatment, only 
a few  studies have been done to describe the outcomes of these patients.(6-9) 
Patients included in the present study received IVB for stage 3 disease with plus in zone 
I, for aggressive posterior ROP (AP-ROP) and for posterior threshold disease. For the 
purposes of this study these three indications for IVB are collectively referred to as 
aggressive posteriorly located retinopathy of prematurity (henceforth abbreviated 
APLROP). 
This study, directed to add to the evidence-base of IVB treatment, is a retrospective chart 
review to determine the outcomes of premature and low birth weight infants who 




Albert Luthuli Central Hospital (IALCH). The outcomes were assessed according to post-
interventional progression, recurrence, regression, full vascularisation and complications 
that occurred during the follow up. The defaulters were analysed separately. 
Some of the outcomes have not been described in the literature before and results of this 
study can therefore contribute to improved future treatment protocols and help to 
alleviate the burden of visual morbidity caused by ROP. 
Research method and design 
Study design 
A retrospective descriptive chart review was done by analysing the clinical documents 
entered for these patients on the computer database (Soarian system) at IALCH between 
January 2009 and December 2016. The demographical information was recorded 
including race, gender, birth weight and gestational age (GA). The corrected gestational 
age (CGA) at the time of intervention and subsequent full vascularisation, as well as the 
period in weeks between injection and full vascularisation, were documented. The 
response to IVB was assessed by analysing the patient’s clinical documents for 
progression, recurrence, regression and further vascularisation. The structural outcomes 
were analysed, looking at progression to retinal detachment, full vascularisation and 
complications such as myopia, macular dragging and permanent or inoperable retinal 
detachment. Patients who defaulted treatment or follow up, were excluded from the main 
analysis, but were analysed separately.  
Setting  
IALCH is a tertiary hospital treating patients from across KwaZulu-Natal. The 
ophthalmology clinic at IALCH receives patients from several peripheral ophthalmology 




the ROP Working Group of South Africa.(10) Patients were diagnosed according to the 
International Classification of Retinopathy of Prematurity (ICROP).(11) Injections of 
0.625 mg Bevacizumab were administered intravitreally, 1.5 mm from the limbus via 
sterile technique and under general anaesthesia in theatre. Patients were followed up 
until first documentation of full vascularisation with complete regression in both eyes, 
and then referred to the base hospitals.  
Data collection 
Data was collected from the Soarian electronic data base at IALCH and analysed with 
Microsoft Excel. A password was used on the relevant computer to assure patient 
confidentiality. 
Data analyses 
Data were analysed descriptively and means (±SD) were presented for continuous 
variables, and frequencies (%) were presented for categorical variables. All these analyses 
were done using Microsoft excel. 
A Chi-squared test was used to determine whether there was a statistically significant 
difference in the number of documented permanent retinal detachments, between the 
patients who defaulted follow up, and those who complied with further follow up. 
Non-parametric statistics were used to determine whether there was a statistically 
significant difference in the CGA at time of IVB administration, between the group that 
vascularised fully and the group that progressed to retinal detachment. 
Ethical considerations 
The Provincial Health Research Committee (PHRC) and University of KwaZulu-Natal 




Site permission was obtained from Inkosi Albert Luthuli Central Hospital’s medical 





In this sample, the incidence of APLROP in infants diagnosed with ROP steadily 











Sixty-four eyes of 33 patients with APLROP received IVB injections between January 2009 
and December 2016. Ten patients (20 eyes) defaulted follow up to an extent that it 
significantly influenced their outcome. Thus 44 eyes of 23 patients qualified for the study.  
The mean GA was 28.4 ± 1.7 weeks and the mean weight was 0.99 ± 0.2 kg, at birth.  
Of the 23 patients, 18 were black, three were Indian, one was of mixed race and one was 
white, largely mirroring the population demographics of the province.  
The indication for IVB was AP-ROP in 38 eyes, posterior threshold disease in three eyes 
and stage 3 disease in zone I with plus in a further three eyes. 
Figure 1: Number of patients diagnosed with APLROP and injected with IVB during each year 




Seven eyes had a limited PPV after progression to stage 4A/B post IVB and 16 eyes had 
CLT. Three of the 16 eyes had CLT at three to four weeks post IVB due to early 
progression and the rest had CLT at the time of the IVB injection, because during this 
period, the efficacy of IVB was not established yet. Ten of the 16 eyes had CLT in 2011.  
Figure 2 indicates the number of the specific interventional modalities per year of the 
study period.  
Bevacizumab was injected at a mean CGA of 35.2 ± 2.3 weeks. The mean CGA at first 
documentation of full vascularisation was 52 ± 8.8 weeks, which increased to 55 ± 8.7 
weeks when the lasered eyes were excluded. The period between injection and full 
vascularisation was a mean of 17.9 ± 9.5 weeks. Thirty-six eyes (81.8%) regressed and 
vascularised fully or up to the lasered retina. 
The eyes that regressed and vascularised fully received IVB at a mean CGA of 34.9 weeks, 
while the eyes that progressed to retinal detachment received IVB at a mean CGA of 36.3 
weeks, a mean of 1.31 weeks later than the eyes that regressed and vascularised fully. 
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Eight eyes progressed to retinal detachment. Of these, six eyes progressed to stage 4A, 
one eye to stage 4B and one eye to stage 5 disease. The parents of one of the patients that 
progressed to stage 4A refused surgery, thus seven eyes underwent vitrectomies with 
eventual flat retinae in six of these eyes. One eye, initially diagnosed with threshold 
disease described as 12 clock hours of stage 3 disease in zone I with plus and progressing 
to stage 5 after IVB, remained detached after surgery.  At the time of his PPV it was 
documented that there were five retinal holes and a fold over the macula and a decision 
was made not to reoperate due to a poor prognosis for vision. The retinal detachment in 
the eye of the patient where surgery had been refused by the parents did not progress 
but instead the eye developed cicatricial ROP with a dragged, but flat retina at final 
examination.  In total, therefore 43 eyes had documented flat retinae. 
Myopia was documented in ten eyes, eight of which had high myopia. The majority (80%) 
of these received CLT. There were two eyes that had documented macular dragging 
(figure 3).  Of the sixteen that had IVB and CLT, eight eyes (50%) had documented 
myopia, compared to two of 28 eyes (7.1%) only receiving IVB. No recurrence of ROP 




















Of the 20 eyes from the 10 patients who defaulted treatment, five eyes (25%) had 
documented retinal detachments ranging from stage 4B/stage 5 to cicatricial ROP. A Chi-
squared test was used to determine whether there was a statistically significant 
difference in the number of documented permanent retinal detachments between the 
patients defaulting follow up (25%) and those complying with follow up (2.3%). This 
difference was statistically significant (Non-parametric analysis; asymptomatic 
significance 2-sided=0.004, p<0.01).  
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The discussion  
Discussion of key findings 
In this study of patients with APLROP, injected with IVB, a favourable structural 
outcome was seen in the majority of patients and important trends were observed which 
can aid to improve guidelines and management of our ROP patients.   
The incidence of aggressive posteriorly located ROP decreased steadily since a peak in 
2012. The likely explanation for the declining incidence is better neonatal care and better 
oxygen monitoring. 
Of the eyes injected with IVB, 81.8% responded well to IVB and had documented full 
vascularisation after regression of the disease. Eight eyes (18.2%) responded poorly to 
treatment and progressed to retinal detachment. Most of the eyes that progressed to 
detachment also received CLT. Sanghi et al  reported progression to retinal detachment 
in 17.4% of 109 eyes diagnosed with AP-ROP and treated with CLT.(12) Sanghi’s sample 
however was only AP-ROP patients and they were treated with only CLT, it can however 
be concluded that the results in this study were at least as good. Of the 44 eyes in this 
study, 38 eyes had AP-ROP of which 6 eyes progressed to retinal detachment. Therefore 
15.8% of the eyes diagnosed with AP-ROP, progressed to retinal detachment and all of 
these eyes were treated with both bevacizumab and CLT. None of the eyes with AP-ROP 
that were treated with only bevacizumab progressed. Out of the 16 eyes that were treated 
with CLT and bevacizumab 8 eyes progressed (50%) which is a significant high number 
of eyes that progressed among the CLT group. Among the 8 eyes that progressed 6 eyes 
received CLT for zone 1 disease which may be the reason for the poor outcome in this 
subgroup. This study sample however, was not large enough to make significant 





In this study, there was early progression at a mean CGA of 38.9 weeks and thus a mean 
of 2.62 weeks after the IVB injection and in six of the eight eyes, progression shortly 
followed CLT. A more fulminant disease process, necessitating ‘rescue’ laser therapy is a 
possible explanation but it should be considered that the laser treatment could have 
contributed to the progression. It is described that incomplete or aggressive laser therapy 
can worsen the progression of ROP.(13)  There is therefore a suspicion of inadequate or 
aggressive laser therapy in some of the patients in our study population.  
In this study, there were no recurrences in contrast to the BEAT-ROP trial where there 
were late recurrences in the IVB group, at a mean of 16±4.6 weeks after IVB, compared to 
early recurrences at 6.2±5.7 weeks after CLT. (8). A possible explanation for our low 
recurrence rate could be the fact that, unlike the cohort in the BEAT-ROP trial (mean GA 
of 25.4 weeks), our babies were relatively more mature (mean GA of 28.4 weeks) and 
therefore vascularisation occurred before the effect of the bevacizumab had worn off.   
 
Out of the 44 eyes that qualified for the study, the structural outcomes were favourable 
with only one eye with a permanent retinal detachment, ten eyes with myopia and two 
eyes with macular dragging. The rate of complications and poor structural outcomes 
decreased significantly after 2012 as illustrated in figure 3. The structural outcomes in 
patients who received IVB and CLT were poorer than the patients who received IVB only. 
A higher rate of myopia and progression to retinal detachment were documented in the 
combined CLT and IVB group. Myopia was documented in 50% of the eyes that had CLT 
and IVB, while it was only documented in 7.1% of the eyes that had only IVB.  This trend 
was very similar to the outcomes of a follow up study done on the BEAT-ROP 
participants for zone I disease in which very high myopia was documented in 3.8% in the 




followed up long term and therefore refractions were not done on them. As a result, the 
incidence of myopia might be higher than what was documented.   
 
 
Figure 4: Structural outcome comparing IVB and CLT with IVB only 
Vascularisation was delayed and full vascularisation was documented at a mean of 17.9 
± 9.5 weeks post IVB and a mean CGA of 55 weeks in eyes that did not receive laser. These 
findings correlated well with the findings from other studies that also showed delayed 
vascularisation after IVB.(7) This emphasizes the fact that patients who receive IVB need 
to be followed up for longer periods than patients who are treated with other modalities 
such as CLT.(4)  
 
There was a significantly high default rate (30.3%) among the patients diagnosed with 
APLROP. This default rate was less than the 48.8% among patients diagnosed with ROP 
in a large prospective study done at Chris Hani Baragwanath Hospital between 2001 and 
2003, but still high enough to raise concern.(1) There is a trend towards a high default 























rate among ROP patients. Possible reasons for this poor follow up rate could be linked to 
poverty, poor social support structures and lack of transport. The physical and 
psychological burden of having a preterm baby in ICU for a prolonged period can also 
contribute to poor compliance with the management plan. 
 
The percentage of eyes that progressed to permanent or inoperable retinal detachment 
was significantly higher among the patients that defaulted follow up compared to the 
patients that followed up regularly (25% compared to 2.75%).  It is therefore very 
important to have systems in place to encourage regular follow up, but also to recruit 
defaulters. This high default rate and poor outcome among the defaulters have not been 
described in literature before. 
 
There was a trend towards progression to retinal detachment in eyes that received IVB 
relatively later during the course of the disease process. This is also a very important 
finding that has not been described in literature before. The difference in the interval was 
found to be statistically significant. In a condition where the time window to stop the 
neovascular drive is often very small, timeous administration of IVB can make the 
difference between a good and a poor outcome.(10) The exact reason why time is such a 
critical aspect is not known, but it might be related to the contraction of fibrovascular 
membranes post IVB administration.(12) This trend can possibly be explained by the 
equilibrium between connective tissue growth factor and vascular endothelial growth 
factor, and the triggering of the angio-fibrotic switch by anti-VEGF as described by 





CLT was administered less liberally after 2011 especially for zone I disease. 87.5% of the 
CLT in this study occurred in 2011 and 2012 (figure 2). Most of these eyes had zone I 
disease and documented high myopia at later follow up. After 2012 CLT was used much 
less often for zone I disease. This trend was most probably a natural response to the poor 
structural outcomes of these patients. The outcomes of these patients were very similar 
to the outcomes of a follow up trial that was done on the BEAT-ROP patients by Geloneck 
et al in which 51.4% of the patients in the CLT-group had documented very high 
myopia.(14) 
Strengths and limitations of this study 
This was a retrospective study and posed the characteristic limitations associated with 
retrospective studies. Different modalities of treatment were used with three different 
indications for IVB, which caused difficulty in ascribing changes to a specific treatment 
modality. Patients were also assessed by multiple doctors with different levels of 
experience which compromised stability in the variables further. The disease entity 
studied is rare and therefore a relatively long study period is needed to acquire a 
meaningful population sample. The outcomes of treated patients were influenced by 
multiple risk factors and comorbidities, which were inconsistently documented in the 
clinical notes. The aim of this study was therefore to observe trends rather than make 
absolute conclusions regarding ROP treatment and outcomes. 
Recommendations for the ROP policy or guidelines 
This study shed some light on a few aspects on which we can work in order to improve 
the quality of management of ROP patients.  
The most important aspect is to inform, educate and counsel parents thoroughly 




better compliance with the treatment and follow up plan. A plan should be in place to 
trace parents who default treatment, such as acquiring collateral contact information or 
liaising with the base hospital or paediatric unit to recruit these patients. 
Detailed and complete clinical note keeping is essential in order to manage these patients 
better but also to monitor outcomes more accurately and to serve as a buffer in case of 
medico-legal litigation. More objective monitoring of ROP by means of fundus 
photography and fluorescein angiography will be of great benefit in ROP management 
and to audit the outcomes.  
There should be better collaboration with the neonatal unit and paediatric department in 
order to improve oxygen monitoring, neonatal care and appropriate or timeous referral 
for screening. A formal protocol will help to standardise ROP management between all 
the relevant role players and to avoid unnecessary deviation and pitfalls.  
CLT of very posterior disease especially zone I disease should be avoided. 
Positive aspects of our ROP management are also highlighted and can be further 
expanded in order to improve the level of care of patients. These include an excellent 
screening facility, good infrastructure, good equipment and a fully functional retinal 
surgery service at the same facility.  
Suggestions for future research 
Safety is still a concern and this study was not powered to evaluate safety aspects of IVB. 
Further studies are needed to investigate the ideal dosage and timing of, as well as 
indications for IVB. Studies are also needed to establish the role of ranibizumab in 
treatment of ROP. A prospective study on ROP will serve a vital role in helping to expand 





Most patients in this study had a favourable structural outcome when they were followed 
up regularly, but very poor outcomes were seen among the patients who defaulted follow 
up. There were also a very high number of patients that defaulted follow up. 
 A longer follow up period is required for babies receiving IVB, as opposed to CLT. Also 
proper counselling and measures to ensure or encourage regular follow up may 
contribute toward a better outcome in patients diagnosed with ROP.(4) 
From this study, it can be concluded that IVB is of great benefit in patients with APLROP, 
though other modalities such as CLT and PPV are still essential in managing some 
patients. Patients with very advanced disease at the first presentation tend to have a 
poorer outcome. Furthermore, because APLROP rapidly progresses, timeous 
intervention without delay is essential.  Later treatment can trigger the angio-fibrotic 
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Inkosi Albert Luthuli Central Hospital  




1.3 Aims (what you hope to achieve) and objectives (how you will achieve your aims) of 
study: 
            (please list) 
 
Aim: To determine the outcome of patients treated with intravitreal bevacizumab for aggressive 
posterior retinopathy of prematurity at Albert Luthuli Hospital since 2011. 
 
Objectives: 
To determine the outcome of AP-ROP patients treated with IVB only.  
To determine the outcome of AP-ROP patients treated with IVB and conventional laser treatment 
(CLT).  
Outcome will be assessed by analysing the following data on each subject: 
• Gestational age, date of birth, birth-weight 
• Post conceptual gestational age at time of intervention 
• Stage and zone of ROP at time of intervention 
• Interventional modalities (IVB, CLT, Pars plana vitrectomy) 




• Recurrence of disease 
• Regression of disease 
• Extent of vascularization  
• Complications 
• Corrected gestational age (CGA) at discharge 
 
1.4 Hypothesis to be tested, or Research Question to be answered: 
Is intravitreal bevacizumab effective in the treatment of aggressive posterior retinopathy of 
prematurity? 
1.5 Summary of the proposed research (restrict to 100 words) 
 
A retrospective chart review of the outcome of patients diagnosed with aggressive posterior 
retinopathy of prematurity and treated with intravitreal bevacizumab at Inkosi Albert Luthuli 
Central Hospital since January 2011. 
1.6 Keywords (for database):  
Intravitreal bevacizumab, Aggressive posterior retinopathy of prematurity 
1.7 Background and Literature Review (maximum 1 page):  
In middle income countries including South Africa, retinopathy of prematurity (ROP) is emerging 
as a ‘third epidemic’ and is one of the most common causes of preventable blindness in preterm 
neonates.1 Each year 16000 babies are at risk of ROP.1 The prevalence of blindness due to ROP is 
50000 worldwide.2 
ROP affects premature infants of very low birth weight and causes a proliferative retinopathy. The 
immature retina is incompletely vascularised and is very susceptible to oxygen damage.3 The 
incompletely vascularised retina produces vascular endothelial growth factor (VEGF). ROP is 
caused by rebound excessive VEGF production induced by the increased metabolic demand of the 
growing eye.3 
Preventing retinal detachment or retinal scarring, and improving the visual outcome are the primary 
goals of ROP treatment.4 Treatment modalities include pharmacologic blockade of VEGF, ablation 
of the peripheral avascular retina, and surgical intervention.4 
Conventional laser treatment (CLT) of the avascular immature retina in infants with threshold 




extensive destruction of the peripheral retina, causing reduction in peripheral visual fields, the 
laborious nature of the treatment as well as the high level of training required to administer.4 
Premature babies are also exposed to the risks of relatively longer general anaesthesia. 
Complications of laser treatment include anterior segment ischemia and burns of the cornea, iris and 
cataract.4 CLT can also induce cystoid macular oedema and myopia. According to the CRYO-ROP 
trial and ETROP trial the recurrence rates with conventional laser therapy are up to 50% for zone I 
disease and up to 20% for zone II posterior disease.2 Therefore Zone 1 disease treated with CLT has 
a relatively high recurrence rate. 
Aggressive posterior retinopathy of prematurity (AP-ROP) is a rare condition and is characterised 
by the prominence of plus disease, posterior location (Zone 1 or posterior zone 2) and poorly 
defined nature.3 If not treated appropriately it often progress to stage 5 disease.3 CLT is efficient in 
the treatment of most ROP cases. However, in AP-ROP, the disease often progress, despite 
extensive laser treatment.5 Laser-treated eyes have a poor anatomical and functional outcome, with 
a high prevalence of retinal detachments.5 CLT for AP-ROP is also technically and practically 
demanding due to opacities in the media and an extensive part of the central and peripheral retina 
is destroyed by laser treatment.5 
 
Intravitreal bevacizumab (IVB) has been successfully used both as monotherapy and in combination 
with CLT, with/without vitrectomy.2 The BEAT-ROP study has provided evidence of a significant 
reduction of retinal detachments in zone I ROP stage 3+ disease after IVB monotherapy.2 IVB in zone 
1 disease also showed a significantly lower recurrence rate compared to laser and significantly fewer 
complications (such as dragging of the macula and retinal detachments).2 In eyes with zone II 
disease, there was no significant difference in recurrence rates between the treatment groups.2 
Development of peripheral retinal vessels continued after treatment with IVB, but conventional laser 
therapy led to permanent destruction of the peripheral retina.2 The timing of recurrence was much 
later in subjects treated with IVB (16 weeks compared to 6 weeks).4 In very mild stage 3+ ROP that 
might regress spontaneously, IVB averts the complications of CLT. Furthermore, IVB allows for the 
successful treatment of very extensive stage 3+ ROP, both type 1 (standard) and type 2 (AP-ROP).2 
The findings of the BEAT-ROP study support a change in policy regarding treatment for AP-ROP. 




ROP with IVB. Therefore, further studies are needed to analyse the outcome of patients diagnosed 
with AP-ROP and treated with IVB. 
1.8      Key References:       (Give approximately 5 key references) 
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and treatment of retinopathy of prematurity (ROP). South African Med J. 2013;103:116–25. 
2. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 
3+ retinopathy of prematurity. N Engl J Med. 2011; 364(7):603–15. 
3. Kanski, JJ, Bowling, B. Clinical ophthalmology. A Systematic Approach. 7th ed. 
Edinburgh:Saunders  Elsevier; 2011. p. 573-5. 
4. Yanoff, M, Duker, JS. Ophthalmology, 4th ed. Edinburgh: Elsevier; 2013. p. 535-9. 
5. Spandau U, Tomic Z, Ewald U, Larsson E, Åkerblom H, Holmström G. Time to consider a 




2.       PLAN OF INVESTIGATION FOR STUDY 




2.1     Is this a retrospective chart review with no human 
contact?    
Yes  No  
2.2     Is this a study of stored tissue? Yes  No  
2.3     Are host genetic factors being studied? Yes  No  
2.4    How many hours per week will the PI devote to this project?         
 
        (Timetable the project in terms of the resources and time available)                 3 hours per week 
 




3.1     Has this project been approved by a professional 
statistician? 
          If No, please justify. 
 
Yes  No  
3.2     If answered “yes” to (3.1), provide the name of the statistician:           Prof. B Sartorius 
3.3   Please provide a brief overview of statistical and data analytic considerations, including: 
         How was the number of participants determined? Please include assumptions made in any power analysis (e.g. control incidence or mean and standard 
deviation of primary outcome variable, desired or anticipated effect of treatment or intervention, level of statistical significance  
           and desired power), and list all planned statistical methods to be used. For descriptive studies list statistical operations to be performed. 
 
This is a descriptive study. Continuous variables will be summarized using mean and 
standard deviation (or media and interquartile range if data are skewed or outliers present). 
Categorical variables will be summarized using frequencies. 
 




4.      PARTICIPANTS IN THE STUDY 
4.1   Is this a multi-national study?     
        (If yes, state collaborating countries) 
Yes   No   
4.2    List all sites in South Africa in which the project will be carried i.e.  geographic location 
(e.g. KwaZulu-Natal) and type of place (e.g. hospital, clinic, schools, community etc). 
Geographic location: KwaZulu-Natal, Durban 
Type of place: Inkosi Albert Luthuli Central Hospital  
4.3    Source:  
      (Please indicate number per group) 















4.4    Age (human studies) 
      (Please indicate number per group) 


























4.6         Demographic profile of participants (please tick ALL appropriate boxes below.) 
 
4.6.1      Gender:                   Female                   Male 
 
4.6.2     Population Group:    Black                      Coloured                     Indian                    White 
 
4.6.3     Language Group/s: Specify……… Zulu, English, Afrikaans ………………… 
 
4.7    Describe the recruitment process in detail for all groups.       Retrospective chart review 
4.8    Will incentives be offered to facilitate recruitment? 
          (If yes, describe in detail) 
Yes  No  N/
A 
 
4.9    Will participants be reimbursed in some way for 
participation?  
           (If yes, describe in  detail) See  SA DoH Guidelines on BREC Website 








4.10 Will reimbursement for participants and investigators be in 
accordance with: (If no, please explain) 
• Guidelines for Good Practice in the Conduct of Clinical Trials 
in Human Participants in South Africa: Department of Health 
(2006) and; 
• Ethics in Health Research: Principles, Structures and 
Processes: (2004)? 
• Current SA DoH Guidance on reimbursement (See BREC website) 
Yes  No  N/
A 
 
4.11   Will participants be insured against research related injury? 
(If yes, please provide details;  If no, please provide rationale) 
            Mandatory for Clinical Trials 
Yes  No  N/
A 
 
4.12   List in detail the inclusion and exclusion criteria. 
 
Inclusion criteria: 
• Premature/Low birth weight neonates that presented/were born at IALCH since 
2011, that were diagnosed with AP-ROP and treated with intravitreal 
bevacizumab. 
• Defaulters or patients that were not followed up for long enough to complete the 
treatment process were included for statistical purposes. 
Exclusion criteria: 






5.      POTENTIAL RISKS OR DISCOMFORT 
5.1     Can the project have any potential risks or discomfort on participants, 
members of the public, researchers, field staff or the physical 
environment?  
Yes  No   
5.2     If “yes” to (6.1)  indicate, for each study group/arm, the potential additional risks as follows: 
5.2.1    Biological risks 
5.2.2    Psychological risks 
5.2.3    Social Risks 
5.2.4    Legal risks 
5.2.5    Financial risks 
5.2.6    Other risks 
 
5.3     Please detail steps that will be taken to minimise the risks indicated above: 
5.3.1    Biological risks 
5.3.2    Psychological risks 
5.3.3    Social Risks 
5.3.4    Legal risks 
5.3.5    Financial risks 
5.3.6    Other risks 
 
6.      INFORMED CONSENT: GIVEN TO PARTICIPANTS 
See SAMPLE INFORMATION SHEET AND CONSENT FORM ON UKZN BREC WEBSITE at 
http://research.ukzn.ac.za/Libraries/Notices2011/BREC_Informed_consent_form_sflb.sflb.ashx 
 
Other consent forms are acceptable provided that they contain at least the essential elements outlined in the current 
UKZN BREC Terms of Reference (ToR) and Standard Operating Procedures (SoP) available at 
http://research.ukzn.ac.za/Research-Ethics/Biomedical-Research-Ethics.aspx   
  
If necessary, information sheets and consent forms, after ethics approval of the English version, must be translated into 
appropriate local languages and submitted to BREC for further approval prior to implementation, with a copy of the 
translator’s certificate, and back translations if applicable.  
  
The correct and complete contact details for the UKZN Biomedical Research Ethics Committee should be in the 
information sheets and consent forms as follows:  
  
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION  
Research Office, Westville Campus  
Govan Mbeki Building  
University of KwaZulu-Natal 
Private Bag X 54001, Durban, 4000  
KwaZulu-Natal, SOUTH AFRICA  
Tel: 27 31 2602486 - Fax: 27 31 2604609  

































































Structure and style of your original research article 
The page provides an overview of the structure and style of your original research article to be submitted to 
the African Vision and Eye Health. An original article provides an overview of innovative research in a particular 
field within or related to the focus and scope of the journal, presented according to a clear and well-structured 
format (between 3500 and 7000 words with a maximum of 60 references). Compulsory as a supplementary file: 
Ethical clearance letter/certificate. 
When presenting your article in English. Please use British English, that is, according to the Oxford English 
Dictionary. Avoid Americanisms (e.g. use ‘s’ and not ‘z’ spellings). Consult the Oxford English Dictionary when 
in doubt and remember to set your version of Microsoft Word to UK English. 
Language: Manuscripts must be written in British English or French. 
Line numbers: Insert continuous line numbers. 
Font type: Palatino  
Symbols font type: Times New Roman  
General font size: 12pt  
Line spacing: 1.5 
Headings: Ensure that formatting for headings is consistent in the manuscript. 
First headings: normal case, bold and 14pt 
Second headings: normal case, underlined and 14pt 
Third headings: normal case, bold and 12pt 
Fourth headings: normal case, bold, running-in text and separated by a colon. 
Our publication system supports a limited range of formats for text and graphics. Text files can be submitted in 




Microsoft Word (.doc): We cannot accept Word 2007 DOCX files. If you have created your manuscript using 
Word 2007, you must save the document as a Word 2003 file before submission. 
Rich Text Format (RTF) documents uploaded during Step 2 of the submission process. Users of other word 
processing packages should save or convert their files to RTF before uploading. Many free tools are available 
that will make this process easier. 
 For full details on how to ensure your manuscript adheres to the house style, click here. 
The structure and style of your original article 
Page 1 
The format of the compulsory cover letter forms part of your submission, is on the first page of your 
manuscript and should always be presented in English. You should provide all of the following elements: 
Full author details: Provide title(s), full name(s), position(s), affiliation(s) and contact details (postal address, 
email, telephone and cellular number) of each author.  
Corresponding author: Identify to whom all correspondence should be addressed. 
Summary: Lastly, a list containing the number of words, pages, tables, figures and/or other supplementary 
material should accompany the submission. 
Page 2 and onwards 
Title: The article’s full title should contain a maximum of 95 characters (including spaces). 
Abstract: The abstract, written in English, should be no longer than 250 words and must be written in 
the past tense. The abstract should give a succinct account of the objectives, methods, results and significance 
of the matter. The structured abstract for an Original Research article should consist of six paragraphs labelled 
Background, Aim, Setting, Methods, Results and Conclusion. The journal can translate into French if this is 
difficult for you. 
Background: Summarise the social value (importance, relevance) and scientific value (knowledge gap) that 
your study addresses. 
Aim: State the overall aim of the study. 
Setting: State the setting for the study. 
Methods: Clearly express the basic design of the study, and name or briefly describe the methods used without 
going into excessive detail. 
Results: State the main findings. 




Do not cite references and do not use abbreviations excessively in the abstract. 
The following headings serve as a guide for presenting your research in a well-structured original article. As an 
author you should include all first-level headings, but subsequent headings (second- and third-level headings) 
can be changed. 
Introduction (first-level heading) 
The introduction must contain your argument for the social and scientific value of the study, as well as the aim 
and objectives: 
Social value: The first part of the introduction should make a clear and logical argument for the importance or 
relevance of the study. Your argument should be supported by use of evidence from the literature. 
Scientific value: The second part of the introduction should make a clear and logical argument for the 
originality of the study. This should include a summary of what is already known about the research question 
or specific topic, and should clarify the knowledge gap that this study will address. Your argument should be 
supported by use of evidence from the literature. 
Conceptual framework: In some research articles it will also be important to describe the underlying theoretical 
basis for the research and how these theories are linked together in a conceptual framework. The theoretical 
evidence used to construct the conceptual framework should be referenced from the literature.  
Aim and objectives: The introduction should conclude with a clear summary of the aim and objectives of this 
study. 
Research methods and design (first-level heading) 
The methods should include: 
Study design (second-level heading): An outline of the type of study design. 
Setting (second-level heading): A description of the setting for the study; for example, the type of community 
from which the participants came or the nature of the health system and services in which the study is 
conducted. 
Study population and sampling strategy (second-level heading): Describe the study population and any 
inclusion or exclusion criteria. Describe the intended sample size and your sample size calculation or 
justification. Describe the sampling strategy used. Describe in practical terms how this was implemented. 
Intervention (if appropriate) (second-level heading): If there were intervention and comparison groups, 
describe the intervention in detail and what happened to the comparison groups.  
Data collection (second-level heading): Define the data collection tools that were used and their validity. 
Describe in practical terms how data were collected and any key issues involved, e.g. language barriers. 
Data analysis (second-level heading): Describe how data were captured, checked and cleaned. Describe the 




Ethical considerations (second-level heading): Approval must have been obtained for all studies from the 
author's institution or other relevant ethics committee and the institution’s name and permit numbers should 
be stated here. 
Results (first-level heading) 
Present the results of your study in a logical sequence that addresses the aim and objectives of your study. Use 
tables and figures as required to present your findings. Use quotations as required to establish your 
interpretation of qualitative data. 
All units should conform to the SI convention and be abbreviated accordingly. Metric units and their 
international symbols are used throughout, as is the decimal point (not the decimal comma). 
Discussion (first-level heading) 
The discussion section should address the following four elements: 
Key findings: Summarise the key findings without reiterating details of the results. 
Discussion of key findings: Explain how the key findings relate to previous research or to existing knowledge, 
practice or policy. 
Strengths and limitations: Describe the strengths and limitations of your methods and what the reader should 
take into account when interpreting your results. 
Implications or recommendations: State the implications of your study or recommendations for future research 
(questions that remain unanswered), policy or practice. Make sure that the recommendations flow directly 
from your findings. 
Conclusion (first-level heading)  
Provide a brief conclusion that summarises the results and their meaning or significance in relation to each 
objective of the study. 
Acknowledgements (first-level heading)  
If, through your study, you received any significant help in conceiving, designing or carrying out the work, or 
received materials from someone who did you a favour by supplying them, you must acknowledge their 
assistance and the service or material provided. Authors should always acknowledge outside reviewers of 
their drafts and any sources of funding that supported the research. 
Competing interests (second-level heading): A competing interest exists when your interpretation of data or 
presentation of information may be influenced by your personal or financial relationship with other people or 
organisations that can potentially prevent you from executing and publishing unbiased research. Authors 
should disclose any financial competing interests but also any non-financial competing interests that may cause 
them embarrassment were they to become public after the publication of the manuscript. Where an author has 
no such competing interests, the listing will read as follows: ‘The authors declare that they have no financial or 
personal relationship(s) that may have inappropriately influenced them in writing this article.’    
Authors' contributions (second-level heading): This section is necessary to give appropriate credit to each 




with their affiliation at the time of the study and completion of the work. An ‘author’ is generally considered to 
be someone who has made substantive intellectual contributions to a published study. Contributions made by 
each of the authors listed can follow the example below (please note the use of authors’ initials): 
J.K. (University of Pretoria) was the project leader, L.M.N. (University of KwaZulu-Natal) and A.B. 
(Stellenbosch University) were responsible for experimental and project design. L.M.N. performed most of the 
experiments. P.R. (Cape Peninsula University of Technology) made conceptual contributions and S.T. 
(University of Cape Town), U.V. (University of Cape Town) and C.D. (University of Cape Town) performed 
some of the experiments. S.M. (Cape Peninsula University of Technology) and V.C. (Cape Peninsula University 
of Technology) prepared the samples and calculations were performed by C.S. (Cape Peninsula University of 
Technology). 
References (first-level heading)  
Begin the reference list on a separate page, and give no more than 60 references in all. The African Vision and 
Eye Health uses the Vancouver referencing style, details of which can be downloaded from the journal 
website. Note: No other style will be permitted. 
 
Publisher House Style for authors 
Please select the applicable link below: 
Language usage 
Tables, figures and photographs 
Guidelines for Math 
Unicode fonts 
Fonts: Please use standard (UNIcode) fonts such as Palatino, Times New Roman, Helvetica and Symbol. Fonts 
that have not been embedded will usually be replaced by Courier, resulting in character loss or realignment. 
Creatives: Please supply images as the size intended for final publication. Resizing of images is time 
consuming and can result in loss of quality. 
 
Types of articles published by the African Vision and Eye Health↑  
Most articles published by the African Vision and Eye Health follow a specific format, as listed below: 
Original research articles: These are reports on complete, comprehensive pieces of original research 
dealing with the exploration of issues and experiences relating to, and supporting, opthamology and 
optometrist best-practice development through research learning and problem-based knowledge sharing 
across the African continent. (Maximum 7000 words; 60 references.) Compulsory as a supplementary file: 




Review articles: The review article informs a broad readership about fields in which there have been 
recent, important advances of immense, fundamental significance and highlights unresolved questions and 
future directions (between 2500 and 4000 words; abstract optional but compulsory for long reviews). 
Notes: Short, Research and Technical Notes. 
Occasionally there may be a Thesis Abstract, Book Reviews, Matters Arising or Letters to the Editor. These 
items are per invitation from the Editor-in-Chief. 
References: Begin the reference list on a separate page. The African Vision and Eye Health uses the Vancouver 
referencing style. Note: no other style will be permitted.  
Submit:    New submission |    Revised submission |    Thesis abstract 
 Learn how to ensure your manuscript adheres to the AOSIS Publishing house style. 
The submission process can be interrupted at any time; when users return to their journal’s personalised 
section, they can continue from where they left off. 
 
Language usage ↑ 
General elements 
Quotations: Use single quotation marks for quotations. For quotations within quotations, use double quotation 
marks. Quotations of more than 30 words are to be indented. Do not use quotation marks for indented 
quotations unless it is direct speech (e.g. interviewee responses). 
En dashes and hyphens: Use an en dash (i.e. extended hyphen that can be found in the Insert box under 
Symbols in Microsoft Word) in ranges of numbers and dates. Use hyphens only for words that are hyphenated. 
Dates: Format dates as ‘02 October 2006’, except at the beginning of sentences where numerals and dates 
should either be spelt out or the sentence should be rearranged. 
Percentage: The per cent symbol (%) is used in conjunction with all numbers (e.g. 12%). Numbers that have 
been written out will appear with ‘per cent’ (e.g. five per cent). 'Percentage' is used in a general sense. 
Numbers: Numbers from one to nine must be written out. Numbers from 10 onwards, must be used as 
numerals, except at the beginning of a sentence. 
Spacing and punctuation: There should be one space (and not two) between sentences; one space before unit 
terms (e.g. 5 kg, 5 cm, 5 mmol, 5 days, 5 °C, etc.), but no space before the percentage symbol (%). Thousands 
and millions are marked with a space and not a comma (e.g. 1000,    1 000 000). Ranges are expressed with an 




Units: The use of units should conform to the SI convention and be abbreviated accordingly. Metric units and 
their international symbols are used throughout, as in the decimal point (not the decimal comma), and the 24-
hour clock. 
Foreign language: Foreign language words should be italicised, unless these words are part of normal usage. 
Consult the Oxford English Dictionary if in doubt. 
Acronyms: If a phrase with an established acronym or abbreviation is used and appears more than five times 
in your article, please include the acronym or abbreviation in brackets after first mention of the phrase, and 
then use the acronym or abbreviation only. Please note that you should not define acronyms or abbreviations 
in any of your headings. If either has been used in your abstract, you need to define them again on their first 
usage in the main text. 
Sensitive and political terms 
Race and ethnicity: Try to avoid terms such as 'Blacks' and 'Whites' (please note the use of uppercase letters); 
use instead ‘Black people’, ‘White people’, etc. 'Caucasian', 'Mongoloid', 'Negroid', etc. are generally to be 
avoided except in human population studies. 'Mixed race' is preferable to 'half-caste' or 'Coloured'. 
Disabilities: Avoid using ‘the disabled’, ‘the handicapped’, and instead use  'people with disabilities not 'the 
disabled' or 'people with learning difficulties’, not 'mentally handicapped'. 
Disease 
Avoid health-determined categorisation. 
Use ‘people with diabetes’; not ‘diabetics’. 
Use ‘people with cancer’; not ‘cancer sufferers’. 
Use ‘sexually transmitted infection (STI)’ and not ‘sexually transmitted disease (STD)’. 
Avoid phrasing that dehumanises a patient. Many authors use case (instance of a disease) when they 
mean patient (i.e. the person or individual who is ill with the (disease). 
AIDS 
Ensure that ‘AIDS’ is used for the disease and ‘HIV’ for the  virus, e.g. do not use ‘AIDS carrier’, ‘AIDS 
positive’, ‘AIDS virus’ or ‘catching AIDS or HIV/AIDS’ (avoid using the solidus here).   
‘AIDS sufferer/victim’ is inappropriate; use ‘people with AIDS’.   
Refer to ‘people who practise high-risk activities’ and not ‘high-risk groups’. 
The expression ‘full-blown AIDS’ is unnecessary if the correct distinction has been made between HIV and 
AIDS.  




‘Male’ and ‘female’ are adjectives, so be careful to use them as such (i.e. a male patient and a female frog, but a 35-
year-old man, a French woman and a group of 25 men and 35 women).   
Sexuality: Avoid the terms ‘homosexual activities’ (if achievable within the manuscript’s context, specify which 
activity is being referred to, especially when dealing with medical research.) Avoid using ‘homosexuals’ (specify 
homosexual men or homosexual women).  
Gender: Use gender neutral nouns. Avoid the use of ‘man’ if not specifically referring to men; for example:  
for ‘man’ use ‘humans’  
for ‘man-kind’ use ‘the human race’   
for ‘man-power’ use ‘workforce’   
for ‘man-made fibre’ use ‘synthetic fibre’  
‘He/she’, ‘him/her’ and ‘his/hers’: For ‘he/she’, ‘him/her’ and ‘his/hers’ rather use ‘he or she’, ‘her or him’, 
‘his or hers’ (without a solidus) or change to plural ‘they’. Use inclusive pronouns: use ‘he or she’, or rephrase 
the sentence (rephrasing to the plural form often works):  
✗ … Any observer of changes in publishing technology will perceive that he has need of…  
✓ … Observers of… will perceive that they have… 
Beware of referring to people with stereotypical pronouns (e.g. ‘the doctor treated his patient’; ‘the secretary 
tidied her desk’). 
Geography 
The terms Third World, poor countries and underdeveloped countries should be avoided. 
Developing or non-developed country/society is better, but it is best to specify countries or regions instead. 
Western society and Western World should only be used in relation to geography; otherwise, use developed 
world/society or, even better, specify the countries themselves or the region.  
Tables, figures and photographs ↑ 
In Step 4 of the online submission process, upload all tables, figures, images, and supplementary files. Tables 
should be saved and uploaded as separate Excel (.xls) files with no more than 10 figures and tables in total per 
article. Ensure that all personal identifying information is removed from the supplementary files as indicated 
in the provided instructions. All captions should be provided together on a separate page. Tables and figures 
should use numerical numbers. 
Organise your visual presentation: Once you have read through the analyses and decided how best to present 
each table or figure, think about how you will arrange them within the article. The analyses should tell a story’ 




in the Introduction. The order in which you present the results can be as important in convincing the readers as 
what you actually are saying in the text. 
How to refer to tables and figures in the text: Every figure and table included in the paper must be referred to 
in the body of the text. Use sentences that draw the reader's attention to the relationship or trend you wish to 
highlight, referring to the appropriate figure or table only in parenthesis e.g.: 
Germination rates were significantly higher after 24 h in running water than in controls (Figure 4). 
DNA sequence homologies for the purple gene from the four congeners (Table 1) show high similarity, 
differing by at most 4 base pairs. (Avoid sentences that give no information other than directing the reader to 
the figure or table, e.g. Table 1 shows the summary results for male and female heights at Bates College.) 
Abbreviation of the word ‘Figure’:  When referring to a figure in the text, the word ‘figure’ is never abbreviated 
as ‘Fig.’; the same rule applies to the usage of ‘table’. Both words are spelled out completely in descriptive 
legends.  
How to number tables and figures: Figures and tables are numbered independently, in the sequence in which 
you refer to them in the text, starting with Figure 1 and Table 1. If, in revision, you change the presentation 
sequence of the figures and tables, you must renumber them to reflect the new sequence. 
The acid test for tables and figures: Any table or figure you present must be clear, well-labelled, and described 
by its legend to be understood by your intended audience without reading the results section. That is, it must 
be able to stand alone and be interpretable. Overly complicated figures or tables may be difficult to understand 
in or out of context, so strive for simplicity whenever possible.  
Descriptive legends or captions: To pass the acid test above, a clear and complete legend (sometimes called a 
caption) is essential. Like the title of the article itself, each legend should convey as much information as 
possible about what the table or figure intends to tell the reader: 
the results that are being shown in the graph(s), including the summary statistics plotted  
the organism studied in the experiment (if applicable) 
a context for the results: the treatment applied or the relationship displayed, etc.  
location (only if a field experiment) 
specific explanatory information needed to interpret the results shown (in tables, this is frequently done as 
footnotes)  
culture parameters or conditions if applicable (temperature, media, etc.) 
sample sizes and statistical test summaries, as they apply 




Example:  Figure 1: Height frequency (%) of White Pines (Pinusstrobus) in the Thorncrag Bird Sanctuary, 
Lewiston, Maine, before and after the Ice Storm of 1998. Before, n = 137, after, n = 133. Four trees fell during the 
storm and were excluded from the post-storm survey.  
 
Note: Questions frequently arise about how much methodology to include in the legend, and how much 
results reporting should be done. For laboratory reports, specific results should be reported in the results text 
with a reference to the applicable table or figure. Other than culture conditions, methods are similarly confined 
to the Methods section. 
Footnotes to tables, figures and photographs 
Do not introduce footnotes in the body of the article. Footnotes should be used as follows: 
Copyright and permissions to reproduce should be clearly stated. 
Notes about the table as a whole can be left unlinked (i.e. no linking letters or numbers or symbols) or linked 
to, for example, a relevant column heading.  
Notes about specific parts of the table should be linked using superscript lower case letters (preferred), 
superscript numbers or symbols.  
If lower case letters are used, it could be confused with the table data; use symbols or numbers instead.  
Do not make use of superscript numbers in parentheses (brackets).  
If an abbreviation is mentioned for the first time in a table (e.g. ‘CE’ in Table 1), it must be defined in a footnote 
to that table,  (e.g. HE, Heat event (introduced at weekly intervals). 
Asterisk footnotes are reserved for probability values in tables and usually signify the following values: *, p ≤ 
0.05; **, p ≤ 0.01; ***, p ≤ 0.001. The asterisk is often used in mathematics and should therefore be avoided as a 
footnote symbol. 
Footnote links should be placed after punctuation. The preferred order of footnote symbols in tables (which 
should be superscripted) is  †, ‡, §, ¶ (these are doubled if more footnotes are needed, e.g. ††).  
When superscript numbers or letters are used in text, beware of potential confusion with other superscripts 




Footnotes should be in the following order:   
source notes  
other general notes  
notes on specific parts of the table (following the order in the table itself)  
notes on level of probability  
Guidance on submitting creatives electronically 
Supply your manuscript creatives  in one of the following three preferred formats: 
TIFF: This is an image made up of pixels and is the most universal and most widely supported format across 
Windows and Mac platforms. Most graphics packages can save a file as a TIFF. The higher the resolution (i.e. 
the number of pixels) the sharper the final image.    
Colour or greyscale photographic images: 300dpi 
Line art or combination images: 600/900dpi 
We would recommend using this format for photographic images. 
EPS: An EPS is essentially an envelope for holding text and images. Line art can be produced as an EPS (in 
Illustrator, for example). There are virtually no limits to scaling line art saved as an EPS. It can also contain 
TIFF images. However, please ensure that all fonts are embedded (that is, saved as outlines) and that line 
weights are not defined as hairline. 
PDF: This format is, again, like an EPS in that it is an envelope for holding different kinds of images and line 
art. Great care should be taken to ensure that fonts are embedded and that original images are at the correct 
size and resolution before being saved as a PDF. It is possible to save or export as TIFF or EPS from most 
graphics applications, just as it is possible to save direct to a PDF from most graphics packages by using a 
postscript printer driver. PDF creation packages (e.g. Acrobat Distiller) are also now widely available. 
Other file formats 
JPEG: A JPEG compressed TIFF is acceptable as long as the degree of compression is moderate. It is better to 
use a JPEG for online images as a good quality image is achievable even with a high degree of compression. 
GIF: A format suitable for images that contain few colours. Again, this should only be used for images 
intended for the web. 
We cannot guarantee the quality of images supplied in other formats. 
Colour: 




Greyscale art should be saved in greyscale mode. 
CyanMagentaYellowBlack are the base colours used during the printing process. 
Any colour that is to appear in print must be in CMYK mode. 
RedGreenBlue are the colours used by monitors and default scanner settings. Any colour that is to appear 
online must be in RGB mode. 
Guidelines for Math ↑ 
Set display equations in MathType. Each display equation should be in its own MathType object. Each 
MathType object should contain the entire equation, including final punctuation. The equation number should 
be set as Microsoft Word regular text, outside the MathType object, separated by either a tab or a space. 
Set in-text (inline) math in Microsoft Word regular text. Exception: If in-text (inline) math has elements that 
should be stacked or have rules, circumflexes, arrows, or other accents spanning over more than one character, 
set in MathType as ‘Inline Equation.’ 
If any characters cannot be found in Word’s Symbol palette (‘(normal text),’  ‘Times New Roman,’ or ‘Symbol’), 
please set in MathType. 
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Appendix 7: Raw data 
Demographics summary: 
Patient 
nr. Gender Race 
Year of 





Zone 1  
Posterior 
Zone2 Intervention 
1 Male Indian 2016 30 0.11 L AP-ROP Stage 3+   B 
            R AP-ROP Stage 3PP   B 
2 Male Black-African 2015 32 0.96 R AP-ROP   Stage 3+ B 
3 Male Black-African 2014 26 0.85 L AP-ROP Stage 3+   B+C 
            R AP-ROP Stage 3+   B 
4 Male Black-African 2014 29 1.35 L AP-ROP N   B+C 
            R AP-ROP N   B 
5 Female Black-African 2014 27 0.85 L S3Z1+ Stage 3+   B 
            R S3Z1+ Stage 3+   B 
6 Female Black-African 2013 29 1.12 L AP-ROP N   B 
            R AP-ROP N   B 
7 Male Black-African 2013 26 1 L S3Z1+ Stage 3+   B 
            R AP-ROP Stage 2+   B 
8 Female Black-African 2012 29 1.18 L AP-ROP   Stage 3+ B+C 
            R AP-ROP   Stage 3+ B+C 
9 Female Black-African 2012 28 0.74 L AP-ROP Stage3+   B+P 
            R AP-ROP Stage3+   B+P 
10 Female Black-African 2012 28 1.17 L AP-ROP Stage 3+   B 
            R AP-ROP Stage 2+   B 
11 Male Indian 2012 29 1.1 L AP-ROP Stage 2+   B 
            R AP-ROP Stage 2+   B 
12 Male Black-African 2012 29 0.89 L AP-ROP Stage 2+   B 
            R AP-ROP Stage 2+   B 
13 Female Black-African 2012 30 1.27 R Th Stage 3+   B+C+P 
14 Female Black-African 2012 29 1.2 L AP-ROP N   B 
            R AP-ROP N   B+C+P 
15 Female White 2012 24 0.82 L AP-ROP Stage 2+   B 
            R AP-ROP Stage 2+   B 
16 Female Black-African 2012 28 0.97 L AP-ROP   Stage 2+ B 
            R AP-ROP   Stage 2+ B 
17 Female Black-African 2011 31 1.065 L AP-ROP Stage 1+   B 
            R AP-ROP Stage 1+   B 
18 Male Mixed race 2011 29 1.1 L AP-ROP Stage 1+   B 
            R AP-ROP Stage 1+   B 
19 Female Black-African 2011 27 0.87 L AP-ROP   Stage 3+ B+C 
            R AP-ROP   Stage 3+ B+C 
20 Male Indian 2011 28 0.99 L AP-ROP Stage 3+   B+C 
            R AP-ROP Stage 3+   B+C 
21 Female Black-African 2011 29 1.1 L AP-ROP Stage 3+   B+C 
            R AP-ROP Stage 3+   B+C 
22 Female Black-African 2011 29 1.1 L AP-ROP Stage 2+   B+C+P 
            R AP-ROP Stage 2+   B+C+P 
23 Female Black-African 2011 28 0.95 L Th Stage 3+   B+C 
            R Th Stage3+   B+C+P 
Mean       28.4 0.9893           
                      




    
Eyes that vascularized fully or up 
to laser demarcation        
    Only eye in the main analyses that had a permanent retinal detachment    
  GA:Gestational age in weeks, BW:Birth weight in kilogram, L:Left, R:Right      
  
AP-ROP:Aggressive posterior ROP, Th:Threshold disease, Z1S3+:Stage 3with plus disease in zone 1, PP:Pre 
plus disease;N:Not noted in clinical notes   






Outcome and intervention summary 
 
Patient nr Avastin+CGA Laser+CGA PPV+CGA Regression Progression
Period between 
injection and vasc
CGA(wks) at full 
vascularization Description of outcome
1 36 ✓ 16 52
36 ✓ 16 52 Some traction or dragging temporal,Gliosis at 3 o clock
2 38 ✓ 5 43
3 34 37 ✓ 17 51
34 ✓ 17 51
4 35 38 Father refused ✓ Flat retina,some macular dragging.Parents refused PPV for S4A
35 ✓ 20 55
5 34 ✓ 13 47
34 ✓ 13 47
6 33 ✓ 31 64
33 ✓ 31 64
7 34 ✓ 34 68
34 ✓ 34 68
8 41 41 ✓ 13 54 Vasc up to laser scars
41 41 ✓ 13 54 Vasc up to laser scars
9 38 41 ✓ 48 Flat retina with nasal gliosis post PPV for nasal S4a
38 41 ✓ 48 Flat retina with nasal gliosis post PPV for nasal S4a
10 34 ✓ 17 51
34 ✓ 17 51
11 32 ✓ 21 53 High myopia
32 ✓ 21 53 High myopia
12 32 ✓ 28 60
32 ✓ 18 50
13 36 36 37 ✓ Funnel detachment
14 35 ✓ 17 52
35 39 39 ✓ Flat retina with nasal gliosis post PPV for S4B
15 33 ✓ 19 52
33 ✓ 19 52
16 36 ✓ 11 47
36 ✓ 11 47
17 37 ✓ 19 56
37 ✓ 19 56
18 35 ✓ 41 76
35 ✓ 41 76
19 35 35 ✓ 11 46 Myopia
35 35 ✓ 11 46 Myopia
20 39 39 ✓ 5 44 High myopia
39 39 ✓ 5 44 High myopia
21 33 33 ✓ 7 40 High myopia
33 33 ✓ 7 40 High myopia
22 37 37 45 ✓ High myopia.Flat retina post PPV for S4a
37 37 45 ✓ High myopia.Flat retina with nasal gliosis post PPV for S4a
23 34 34 ✓ 8 41
34 34 38 ✓ Flat retina.Nasal and superotemporal gliosis post PPV for S4a
Mean 35.18181818 36.75 40.85714286 52.60526316
PRP (laser) PPV Regressed ProgrAvg time between Avastin and vascVasc
44 eyes 16 7 eyes 36 eyes 8 eyes 17.94444444 38 pts
86.36%







Period in weeks between injection and vascularization 
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